Division of Orthopaedic Surgery News & Announcements

Learn about novel findings from our Children’s Hospital of Philadelphia researchers.

Identified by CHOP researchers, palovarotene is the first drug approved (in Canada) for fibrodysplasia ossificans progressiva, a severe bone disease.

Palovarotene is the first approved drug against fibrodysplasia ossificans progressiva (FOP), a rare and often fatal disease.

This week’s In the News features new study on measuring vision changes in patients with neurofibromatosis type 1, and other research highlights.

CHOP researchers identified the drug, palovarotene, to treat fibrodysplasia ossificans progressive (FOP).

CHOP and its individual departments ranked high in U.S. News and World Report’s Best Children’s Hospitals for 2021-2022.

The February Featured Research Trainee, Kaylia Duncan, reflects on Black History Month and her scientific career.

Study shows deep decline in number of pediatric patients visiting the emergency department for asthma treatment during first month of COVID-19 pandemic. This and more In the News.

U.S. News &World Report once again ranked CHOP as one of the top children’s hospitals in the United States

CHOP stays on top of COVID-19 research, from multisystem inflammatory syndrome in children to social distancing’s impact on fractures.